Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

18 nov. 2025 06h00 HE | Source: Mutuum Finance

Mutuum Finance (MUTM) Hits 90% Allocation in Phase 6 Ahead of Upcoming V1 as Funding Approaches $19M

DUBAI, United Arab Emirates, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Momentum continues to build around Mutuum Finance (MUTM) as the project approaches two major milestones at the same time: the...
18 nov. 2025 06h00 HE | Source: MediciNova, Inc.

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...
18 nov. 2025 03h33 HE | Source: Mutuum Finance

New Crypto Mutuum Finance (MUTM) Reports $18.8M Raised and Strong Q4 Progress as V1 Launch Approaches

DUBAI, United Arab Emirates, Nov. 18, 2025 (GLOBE NEWSWIRE) -- A growing number of investors are watching one particular new crypto project as Q4 unfolds. Activity around its ecosystem has been...
18 nov. 2025 01h00 HE | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer

At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of-care endocrine monotherapyThese unprecedented results support its...
17 nov. 2025 23h00 HE | Source: Apollomics Inc.

Apollomics Announces Changes to its Board of Directors and Composition of Committees

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today...
17 nov. 2025 17h30 HE | Source: Artisan Therapeutics

Artisan Therapeutics and Tulex Pharmaceuticals Announce Positive Phase 2a Results for ART-501, a Novel Oral Liquid Extended-Release Formulation for Autism Spectrum Disorder

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the...
17 nov. 2025 16h30 HE | Source: Avalo Therapeutics

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...
17 nov. 2025 08h08 HE | Source: Bleichmar Fonti & Auld

MLTX STOCK LOSS: MoonLake Immunotherapeutics Faces Securities Fraud Class Action due to Drug Trial Results – Contact BFA Law if You Suffered Losses

MoonLake Immunotherapeutics investors that lost money are notified to contact BFA before the December 15, 2025 securities fraud class action deadline.
17 nov. 2025 08h05 HE | Source: Ashvattha Therapeutics

Ashvattha Therapeutics to Showcase Topline Phase 2 Data and Recent FDA Alignment at Upcoming Investor and Ophthalmology Meetings

Company to present 40-week topline results from the Phase 2 study of migaldendranib (MGB), a first-in-class subcutaneous nanomedicine, being developed for the treatment of DME and nAMD FDA alignment...
17 nov. 2025 08h00 HE | Source: Angiex Inc.

Angiex Completes Financings Totaling $31 Million to Advance Phase 1 Dose Escalation of Nuclear-Delivered ADC AGX101 in Patients with Advanced Solid Tumors

CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Angiex Inc., a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, today announced the completion of...

Page précédente

Page suivante